重组人可溶性血栓调节蛋白通过抗炎作用减轻WKY大鼠抗GBM肾小球肾炎
本研究在Wistar-Kyoto大鼠中注射肾毒血清诱导抗GBM肾小球肾炎,从第0天至第6天给予重组人可溶性血栓调节蛋白(RH-TM)或溶剂,第7天处死。结果显示RH-TM治疗组蛋白尿和血肌酐降低,新月体形成和纤维素样坏死肾小球比例显著减少,肾脏巨噬细胞浸润及促炎细胞因子表达下降。机制可能涉及通过降低HMGB1/TLR/MyD88信号通路下调ICAM-1表达。
要点
- RH-TM减轻抗GBM肾炎大鼠的蛋白尿和血肌酐水平
- RH-TM减少新月体形成和纤维素样坏死肾小球比例
- RH-TM抗炎机制与下调HMGB1/TLR/MyD88通路及ICAM-1相关
核心结论
- RH-TM通过抗炎作用减轻实验性抗GBM肾小球肾炎,表现为减少肾小球巨噬细胞浸润和促炎细胞因子表达。
- 其保护效应可能归因于通过降低HMGB1/TLR/MyD88信号通路而下调ICAM-1。
研究设计与样本
- 研究使用Wistar-Kyoto大鼠,注射肾毒血清在第0天诱导抗GBM肾小球肾炎。
- 大鼠从第0天至第6天接受RH-TM或溶剂治疗,第7天处死。
主要发现
- RH-TM治疗组蛋白尿和血肌酐水平降低。
- RH-TM显著减少新月体形成和纤维素样坏死肾小球的比例。
- RH-TM治疗组肾小球ED1+巨噬细胞积累显著减少,肾皮质促炎细胞因子表达降低。
- RH-TM显著降低肾脏和尿液中ICAM-1表达。
- RH-TM显著降低肾皮质TLR-2、TLR-4及其下游衔接蛋白MyD88的mRNA水平。
临床怎么用
- RH-TM可能作为抗GBM肾小球肾炎的潜在抗炎治疗策略,但需进一步临床研究验证。
局限性
- 本研究为动物实验,结果不能直接推广至人类。
- 样本量未在摘要中报告,可能影响统计效力。
- 未报告长期疗效和安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since recombinant human soluble thrombomodulin (RH-TM) has anti-inflammatory properties through neutralizing high-mobility group box 1 protein (HMGB1), the protective effects of RH-TM were examined in anti-glomerular basement membrane (GBM) glomerulonephritis (GN) in Wistar-Kyoto rats. METHODS: Rats were injected with nephrotoxic serum (NTS) to induce anti-GBM GN on Day 0, and were given either RH-TM or vehicle from Day 0 to Day 6. Rats were sacrificed 7 days after NTS injection. RESULTS: RH-TM-treated rats had decreased proteinuria and serum creatinine level. RH-TM significantly reduced the percentage of glomeruli with crescentic features and fibrinoid necrosis. In addition, RH-TM-treated rats had significantly reduced glomerular ED1+ macrophage accumulation as well as reduced renal cortical proinflammatory cytokine expression. Furthermore, RH-TM had a potent effect in reducing intercellular adhesion molecule-1 (ICAM-1) expression in kidneys and urine. RH-TM significantly reduced renal cortical mRNA levels for toll-like receptor -2 and -4, known as receptors for HMGB1, and their downstream adopter protein, myeloid differentiation primary respond protein 88 (MyD88). CONCLUSIONS: We showed for the first time that anti-inflammatory effects, which were characterized by reduced glomerular macrophage influx concomitant with a marked reduction in proinflammatory cytokines, were involved in the mechanism of attenuating experimental anti-GBM GN by RH-TM. The observed effects might be attributable to the downregulation of ICAM-1 by reducing the HMGB1/TLR/MyD88 signaling pathway.
引用
- Tachibana S, Iyoda M, Matsumoto K, et al. Recombinant human soluble thrombomodulin attenuates anti-glomerular basement membrane glomerulonephritis in Wistar-Kyoto rats through anti-inflammatory effects. Nephrol Dial Transplant. 2019. PMID: 29982644. doi:10.1093/ndt/gfy201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。